Wall Street analysts expect that Arsanis Inc (NASDAQ:ASNS) will report earnings of ($0.61) per share for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Arsanis’ earnings. Arsanis reported earnings per share of ($1.68) in the same quarter last year, which suggests a positive year-over-year growth rate of 63.7%. The company is expected to report its next earnings report on Friday, March 8th.
According to Zacks, analysts expect that Arsanis will report full-year earnings of ($2.97) per share for the current year. For the next financial year, analysts expect that the company will post earnings of ($1.55) per share. Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side analysts that follow Arsanis.
Arsanis (NASDAQ:ASNS) last posted its quarterly earnings results on Friday, November 9th. The company reported ($0.76) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.74) by ($0.02).
ASNS traded down $0.01 during trading on Tuesday, hitting $3.37. 981,980 shares of the company traded hands, compared to its average volume of 505,058. The firm has a market cap of $55.69 million and a P/E ratio of -0.21. The company has a debt-to-equity ratio of 0.28, a quick ratio of 5.08 and a current ratio of 5.08. Arsanis has a one year low of $1.15 and a one year high of $28.69.
Large investors have recently modified their holdings of the business. BlackRock Inc. grew its position in Arsanis by 27.1% in the second quarter. BlackRock Inc. now owns 223,797 shares of the company’s stock valued at $812,000 after purchasing an additional 47,777 shares in the last quarter. Granahan Investment Management Inc. MA bought a new position in Arsanis in the second quarter valued at $365,000. Finally, Alambic Investment Management L.P. grew its position in Arsanis by 1,004.6% in the third quarter. Alambic Investment Management L.P. now owns 133,661 shares of the company’s stock valued at $217,000 after purchasing an additional 121,561 shares in the last quarter. Hedge funds and other institutional investors own 64.25% of the company’s stock.
Arsanis, Inc, a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody (mAb) immunotherapies to address infectious diseases. Its lead product candidate is ASN100, a mAb therapeutic in Phase II clinical development for the prevention of staphylococcus aureus pneumonia in mechanically ventilated patients.
Recommended Story: What are the most popular ETFs
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Arsanis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arsanis and related companies with MarketBeat.com's FREE daily email newsletter.